Sep 2026· British Journal of Haematology· 0 citations· 19 references
Medicine
TL;DR
It is demonstrated that SLIT2 may act as a tumour suppressor, while SLIT2 loss impairs myeloid terminal differentiation, suggesting that SLIT2 signalling could serve as a potential therapeutic axis in AML.
Abstract
Acute myeloid leukaemia (AML) is supported by leukaemic stem cells (LSCs), whose continued existence and growth are dependent upon signals derived from their bone marrow (BM) microenvironment. Although the highly conserved glycoprotein slit guidance ligand 2 (SLIT2), implicated in axon guidance, has been proposed to support normal haematopoietic stem cell (HSC) function, its role in AML pathogenesis remains poorly defined. Here, we show that SLIT2 is downregulated in mesenchymal stem cells (MSCs) from AML patients. Patients with higher-than-normal SLIT2 protein levels had better outcomes, independently of classical risk factors. Functionally, knocking down (KD) SLIT2 in MSCs caused a reprogramming of the microenvironment. Specifically, SLIT2-KD in MSCs resulted in increased expression of LSC-supporting genes including C-X-C motif chemokne ligand 12 (CXCL12) and KIT proto-oncogene, receptor tyrosine kinase (KIT), and co-culture of primary AML cells on SLIT2-KD stromal cells prevented myeloid differentiation. Conversely, the addition of recombinant SLIT2 had cytostatic effects on AML cells, resulting in reduced proliferation and reduced clonogenicity in all tested models. Furthermore, in human xenograft models, systemic administration of recombinant SLIT2 resulted in a decrease in leukaemic burden in BM and spleen, delayed disease progression and improved survival. Overall, these data demonstrate that SLIT2 may act as a tumour suppressor, while SLIT2 loss impairs myeloid terminal differentiation, suggesting that SLIT2 signalling could serve as a potential therapeutic axis in AML.
Acute myeloid leukemia (AML) is the most common adult leukemia diagnosis. Bone marrow (BM) niche significantly influences the initiation and progression of AML. However, our knowledge about the effect of leukemic niche on leukemia stem cells (LSC) and leukemogenesis is limited. In this study, we identified an extrinsic...
Cui-Ping Zhang, Xia Yao, Pin-Pin Sui et al.· JCI Insight· 0 citations
The pivotal role of LSCs in disease progression and relapse is highlighted, potential molecular and epigenetic regulators as new targets for intervention are evaluated, and the development of combination treatment strategies to improve TFR rates and move towards curative outcomes is supported.
Jing-Yi Dai, Pan-Pan Zheng, Jian Liu et al.· Frontiers in Bioscience· 0 citations
How inflammation shapes acute myeloid leukaemia (AML) has come under scrutiny, as it may explain the disease’s resistance to immunotherapy approaches. IFNγ has emerged as a key cytokine with paradoxical roles in suppressing and supporting AML growth, and the fundamental question of how leukemic stem cells (LSCs) respon...
C. Pospori, A. Donada, Helena Boutzen et al.· bioRxiv· 0 citations
It is demonstrated that while Cd36 is not essential for MLL-AF9-mediated transformation, its cell-intrinsic expression in leukemic cells suppresses anti-leukemic immunity and accelerates progression, which positions CD36 as a promising target to enhance immune surveillance and limit AML aggressiveness.
Yi-Ting Meng, Wen-Da Zhu, M. Pospiech et al.· Pharmacological Research· 0 citations
RNA-seq following LPCAT3 loss showed that genes differentially expressed were significantly enriched in granulocyte chemotaxis–related pathways, suggesting a role of LPCAT3 in modulation of leukemic differentiation programs and microenvironmental interactions, established that LPCAT3 as a previously unrecognized mediat...
Mu-Tian Cao, L. Cong, Yi-Fei He et al.· Blood Science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.